Filing Details
- Accession Number:
- 0001209191-21-008499
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-08 16:48:37
- Reporting Period:
- 2021-02-05
- Accepted Time:
- 2021-02-08 16:48:37
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1490978 | Schrodinger Inc. | SDGR | Pharmaceutical Preparations (2834) | 954284541 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1797829 | Joel Lebowitz | C/O Schrodinger, Inc., 120 West 45Th Street, 17Th Floor New York NY 10036 | Evp & Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-02-05 | 12,374 | $17.00 | 12,374 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-02-05 | 900 | $97.90 | 11,474 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-02-05 | 10,359 | $99.18 | 1,115 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-02-05 | 1,115 | $99.90 | 0 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2021-02-05 | 12,374 | $0.00 | 12,374 | $17.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
37,122 | 2030-02-05 | No | 4 | M | Direct |
Footnotes
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.56 to $98.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.57 to $99.56, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.60 to $100.20, inclusive.
- This option was granted on February 5, 2020. The shares underlying the option vested with respect to 25% of the shares on February 5, 2021 and the remainder are scheduled to vest in equal monthly installments through February 5, 2024.